Crimson Publishers Publish With Us Reprints e-Books Video articles


Investigations in Gynecology Research & Womens Health

A Study on Sildenafil Citrate in the Treatment of IUGR & Oligohydramnios

Submission: October 10, 2020Published: April 21, 2021

DOI: 10.31031/IGRWH.2021.04.000581

ISSN: 2577-2015
Volume4 Issue2


Intra Uterine Growth Restriction is a challenge to clinicians all over the world because no definitive treatment is available, and many empirical therapies are tried for treating the same. The present study was a multi-centric hospital based prospective observational study conducted in three tertiary care centers in Northern India on 200 patients with late onset IUGR and oligohydramnios. Sildenafil citrate 25mg 8 hourly was given till delivery. All the outcomes were noted and analyzed. After sildenafil therapy, 87 out 0f 90 patients with only IUGR, 35 out of 40 cases of oligohydramnios only and 64 out of 70 patients with IUGR & oligohydramnios both had marked improvement & 14 cases showed no improvement. From this study we concluded that adding sildenafil citrate in the treatment of IUGR and oligohydramnios can be a beneficial option.

Keywords: Intrauterine growth restriction; Oligohydramnios; Sildenafil citrate; Placental insufficiency


IUGR: Intrauterine Growth Restriction; FGR: Fetal Growth Restriction; AC: Abdominal Circumference; AFI: Amniotic Fluid Index; BPP: Biophysical Profile; EFW: Estimated Fetal Weight; MCA: Middle Cerebral Artery; NST: Non-Stress Test; NICU: Neonatal Intensive Care Unit; USG: Ultrasonography

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137